AtriCure, an atrial fibrillation medical device provider, has announced the completion of the previously publicised acquisition of Endoscopic Technologies (doing business as Estech). According to a press release, Estech develops and markets a portfolio of innovative surgical ablation devices that enable physicians to perform a variety of traditional and minimally invasive procedures using Estech’s proprietary temperature controlled radiofrequency energy.
“We are pleased to complete the acquisition of Estech, and we welcome the team to AtriCure. This transaction provides substantial benefits to AtriCure and strengthens our leadership position in the atrial fibrillation market; we are excited about the opportunities that our combined businesses will bring to our customers,” said Mike Carrel, president and chief executive officer of AtriCure.
